Avastin bevacizumab: Development discontinued

Roche said it discontinued development of Avastin for adjuvant colorectal cancer after it missed the primary endpoints in 2 previously reported Phase III trials in the indication (see BioCentury, April 27, 2009 & Sept. 27, 2010). Last month, Avastin plus FOLFOX or XELOX chemotherapy missed the primary endpoint of significantly improving disease-free survival vs. FOLFOX chemotherapy alone in the Phase III AVANT trial. Last year, Avastin plus FOLFOX chemotherapy missed the same primary endpoint vs. FOLFOX chemotherapy alone in the U.S. Phase III NSABP C-08 trial. ...